ADMA BIOLOGICS ANNOUNCES POSITIVE TOP-LINE PHASE III DATA FOR PRIMARY IMMUNE DEFICIENCY DISEASE (PIDD) PATIENTS

RI-002 Phase III Study Achieves Primary Endpoint 

KUALA LUMPUR, Dec 4 (Bernama) -- ADMA Biologics, Inc. (Nasdaq:ADMA), a late-stage biopharmaceutical company that develops, manufactures, and intends to market specialty plasma-based biologics for the treatment and prevention of certain infectious diseases, today announced its lead product candidate RI-002 has demonstrated positive Phase III results and successfully achieved its primary endpoint.

 http://mrem.bernama.com/viewsm.php?idm=23507